ロード中...
Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia
Dasatinib, a second-generation tyrosine kinase inhibitor, is used for treating patients with Philadelphia chromosome (Ph) positive leukemia, especially for those who are resistant or intolerant to imatinib. The common adverse effects associated to its use include myelosuppression, nausea, diarrhea,...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4423504/ https://ncbi.nlm.nih.gov/pubmed/25960668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S83961 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|